Ispecimen Stock In The News

ISPC Stock  USD 1.34  0.07  5.51%   
Our overall analysis of ISpecimen's news coverage and content from conventional and social sources shows investors' bearish mood towards iSpecimen. The specific impact of ISpecimen news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of ISpecimen's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using ISpecimen headlines in addition to utilizing other, more conventional financial analysis modules. Check out ISpecimen Backtesting and ISpecimen Hype Analysis.
For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.

ISpecimen Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
iSpecimen Reports Third Quarter 2023 Financial and Operating Results
https://www.globenewswire.com/news-release/2023/11/02/2772158/0/en/iSpecimen-Reports-Third-Quarter-2023-Financial-and-Operating-Results.html
 Bullish
Macroaxis News: globenewswire.com
iSpecimen Expands Proprietary Provider Network to Help Advance Infectious Disease Research
https://www.globenewswire.com/news-release/2023/10/26/2767388/0/en/iSpecimen-Expands-Proprietary-Provider-Network-to-Help-Advance-Infectious-Disease-Research.html
 Neutral
Macroaxis News: globenewswire.com
iSpecimen Preannounces Third Quarter 2023 Revenue Increase of 60-70% Sequentially
https://www.globenewswire.com/news-release/2023/10/23/2764609/0/en/iSpecimen-Preannounces-Third-Quarter-2023-Revenue-Increase-of-60-70-Sequentially.html
 Neutral
Macroaxis News: globenewswire.com
iSpecimen Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers
https://www.globenewswire.com/news-release/2023/09/28/2751095/0/en/iSpecimen-Launches-Next-Day-Quote-Service-for-Medical-Researchers-and-Biospecimen-Providers.html
 Neutral
Macroaxis News: globenewswire.com
iSpecimen Expands Provider Network to Enhance Support for Women’s Health Research
https://www.globenewswire.com/news-release/2023/09/13/2742367/0/en/iSpecimen-Expands-Provider-Network-to-Enhance-Support-for-Women-s-Health-Research.html
 Neutral
Macroaxis News: globenewswire.com
iSpecimen Announces Organizational Changes to Enhance Operational Efficiencies and Drive Profitability
https://www.globenewswire.com/news-release/2023/09/06/2738831/0/en/iSpecimen-Announces-Organizational-Changes-to-Enhance-Operational-Efficiencies-and-Drive-Profitability.html
 Neutral
Macroaxis News: globenewswire.com
iSpecimen Launches New Virtual Cancer Sequencing Procurement Program
https://www.globenewswire.com/news-release/2023/08/30/2734219/0/en/iSpecimen-Launches-New-Virtual-Cancer-Sequencing-Procurement-Program.html
 Bearish
Macroaxis News: globenewswire.com
iSpecimen Enhances Proprietary Marketplace Platform to Streamline Biospecimen Matchmaking for Researchers and Providers
https://www.globenewswire.com/news-release/2023/08/16/2726242/0/en/iSpecimen-Enhances-Proprietary-Marketplace-Platform-to-Streamline-Biospecimen-Matchmaking-for-Researchers-and-Providers.html
 Neutral
Macroaxis News: globenewswire.com
iSpecimen Introduces New Marketplace Functionality to Streamline Access to Clinical Remnant Samples for Researchers
https://www.globenewswire.com/news-release/2023/08/09/2721530/0/en/iSpecimen-Introduces-New-Marketplace-Functionality-to-Streamline-Access-to-Clinical-Remnant-Samples-for-Researchers.html
 Neutral
Macroaxis News: globenewswire.com
iSpecimen Reports Second Quarter 2023 Financial and Operating Results
https://www.globenewswire.com/news-release/2023/08/02/2716670/0/en/iSpecimen-Reports-Second-Quarter-2023-Financial-and-Operating-Results.html
 Neutral

iSpecimen Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide ISpecimen and other traded companies coverage with news coverage. We help investors stay connected with ISpecimen headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on ISpecimen Stock performance. Please note that trading solely based on the iSpecimen hype is not for everyone as timely availability and quick action are needed to avoid losses.
ISpecimen's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help iSpecimen investors visualize upcoming and past events in order to time the market based on iSpecimen noise-free hype analysis.
ISpecimen stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the ISpecimen earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about ISpecimen that are available to investors today. That information is available publicly through ISpecimen media outlets and privately through word of mouth or via ISpecimen internal channels. However, regardless of the origin, that massive amount of ISpecimen data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ISpecimen news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ISpecimen relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ISpecimen's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ISpecimen alpha.

ISpecimen Largest EPS Surprises

Earnings surprises can significantly impact ISpecimen's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2022-08-04
2022-06-30-0.27-0.3-0.0311 
2024-05-07
2024-03-31-0.27-0.32-0.0518 
2023-05-04
2023-03-31-0.32-0.270.0515 
2022-02-17
2021-12-31-0.22-0.27-0.0522 
2024-03-13
2023-12-31-0.24-0.32-0.0833 
2023-08-02
2023-06-30-0.3-0.39-0.0930 
View All Earnings Estimates

ISpecimen Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to iSpecimen Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Google News at Macroaxis
11th of March 2025
iSpecimen stock hits 52-week low at 1.25 amid sharp decline - Investing.com India
at news.google.com 
Google News at Macroaxis
3rd of March 2025
iSpecimen stock hits 52-week low at 1.54 amid sharp decline - Investing.com
at news.google.com 
Macroaxis News
12th of February 2025
Acquisition by Obf Investments, Llc of 119035 shares of ISpecimen at 666603.0 subject to R...
at MacroaxisInsider 
news
17th of January 2025
iSpecimen Secures Suppliers for Human Metapneumovirus Specimens Amid Growing Concerns
at kalkinemedia.com 
Yahoo News
16th of January 2025
iSpecimen Secures Suppliers for COVID-style hMPV Outbreak
at finance.yahoo.com 
news
2nd of January 2025
iSpecimen Inc. Appoints CEO Robert Bradley Lim as Treasurer and Secretary
at thelincolnianonline.com 
Google News at Macroaxis
23rd of December 2024
iSpecimen stock hits 52-week low at 2.75 amid market challenges - Investing.com
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ISpecimen in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ISpecimen's short interest history, or implied volatility extrapolated from ISpecimen options trading.
When determining whether iSpecimen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of ISpecimen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ispecimen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ispecimen Stock:
Check out ISpecimen Backtesting and ISpecimen Hype Analysis.
For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.
You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ISpecimen. If investors know ISpecimen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ISpecimen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(18.12)
Revenue Per Share
19.19
Quarterly Revenue Growth
(0.04)
Return On Assets
(0.44)
Return On Equity
(1.09)
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ISpecimen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.